Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, toward Phase 2 clinical trials following favorable Phase 1 safety results. The company aims to address demyelination and restore myelin integrity, offering a potential first-in-class approach that directly targets the underlying neurodegeneration in multiple sclerosis rather than solely relying on immune modulation.
Phase 1 studies in healthy volunteers demonstrated that LUCID-MS was generally well tolerated with a favorable safety profile, supporting the progression into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
LUCID-MS is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. According to the company, the therapy may offer a differentiated approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. For more details, the full article can be accessed at https://ibn.fm/AUhNl.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. Quantum BioPharma also retains ownership of 19.84% of Unbuzzd Wellness Inc., which markets the OTC product unbuzzd, and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. Forward-looking statements in this article involve risks and uncertainties, including those set forth under "Risk Factors" in the company's SEC filings. All parties undertake no duty to update this information unless required by law.
